<DOC>
	<DOCNO>NCT01169675</DOCNO>
	<brief_summary>This Phase I study investigate safety BIBW 2992 combination standard dose pemetrexed ( 500mg/m2 ) give 21 day cycle patient advance solid cancer . BIBW 2992 give two different dose schedule ; dose day 1-21 dosing day 1 6 21 day cycle . The use epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKIs ) , include BIBW 2992 demonstrate efficacy solid tumor include non-small cell lung cancer ( NSCLC ) . In addition , pemetrexed demonstrate efficacy approve single agent chemotherapy second-line NSCLC patient adenocarcinoma . The data obtain trial shall allow conclusion whether BIBW 2992 may safely administer advanced cancer patient combination therapy pemetrexed .</brief_summary>
	<brief_title>BIBW 2992 ( Afatinib ) Combination With Pemetrexed Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criterion : 1 . Age 18 old . 2 . Eastern cooperative oncology group performance status 02 . 3 . Life expectancy least 12 week . 4 . Measurable disease accord Response evaluation criterion solid tumor 1.1 criterion . 5 . Written inform consent Exclusion criterion : 1 . Treatment investigational drug within past 28 day prior start therapy 2 . Persisting toxicity clinically significant previous therapy 3 . Patients unwilling unable take folic acid vitamin B12 supplementation 4 . Active brain metastasis 5 . Other active malignancy diagnose within past 3 year 6 . Concomitant intercurrent illness would limit compliance trial requirement 7 . Patients unable unwilling interrupt concomitant administration Nonsteroidal antiinflammatory drug ( NSAIDS ) per pemetrexed prescribe information 8 . Patients receive prior therapy BIBW 2992 9 . Left ventricular function echocardiogram Multiple gate acquisition scan ( MUGA ) less institutional low limit normal 10 . Absolute neutrophil count ( ANC ) less 1,500/mm3 11 . Platelet count less 100,000/mm3 12 . Hemoglobin less 90g/L 13 . Total bilirubin less 26µmol/L 14 . Alanine amino transferase ( ALT ) and/or aspartate amino transferase ( AST ) great 2.5 X ULN , except case know liver metastasis maximum 5 X ULN acceptable 15 . Serum creatinine level great 133µmol/L and/or creatinine clearance ( measure calculate ) less 45 ml/min 16 . History recent gastrointestinal bleeding , obstruction perforation malabsorption syndrome must able swallow BIBW 2992 whole mouth . 17 . History interstitial lung disease 18 . Women men sexually active unwilling use medically acceptable method contraception 19 . Pregnancy breast feed 20 . Known suspect active alcohol drug abuse 21 . Patients unable comply protocol 22 . Has diagnosis human immunodeficiency virus ( HIV ) infection acquire immunodeficiency syndrome ( AIDS ) . 23 . Any known hypersensitivity trial drug excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>